LncRNA HEIH在急性髓系白血病中的表达及临床意义
[Expression and Clinical Significance of LncRNA HEIH in Patients with Acute Myeloid Leukemia].
发表日期：2024 Aug
作者：
Yue Ma, Jia-Jia Li
来源：
MOLECULAR & CELLULAR PROTEOMICS
摘要：
探讨长链非编码RNA（lncRNA）HEIH在急性髓系白血病（AML）患者中的表达及临床意义。选取2019年1月至2020年12月蚌埠医学院第一附属医院收治的50例初诊AML患者（M3除外）。该研究纳入了 30 名非血液恶性肿瘤患者作为对照。检测所有患者中lncRNA HEIH的相对表达水平，分析AML患者临床特征、基因突变、FAB分型、疗效、预后及总生存期（OS）与lncRNA HEIH表达水平的相关性。 AML患者中lncRNA HEIH的表达量显着高于非血液恶性肿瘤患者（P <0.01）。而且，白细胞计数（WBC）高、CEBPA和FLT3突变、疗效差、预后差的AML患者往往表现出较高的lncRNA HEIH表达，而lncRNA HEIH高表达的患者表现出较短的总生存期（OS）。 HEIH在AML患者中表现出独特的分子生物学意义，可能为AML的诊断、监测和靶向治疗提供新的方法。
To investigate the expression and clinical significance of long noncoding RNA(lncRNA) HEIH in patients with acute myeloid leukemia (AML).50 newly diagnosed AML patients (except M3) admitted to the First Affiliated Hospital of Bengbu Medical College from January 2019 to December 2020 were included in the study, with 30 patients with non-hematological malignancies as controls. The relative expression level of lncRNA HEIH in all patients were detected, the correlation of clinical characteristics, gene mutations, FAB classification, efficacy, prognosis and overall survival (OS) of AML patients with the expression level of lncRNA HEIH were analyzed.The expression level of lncRNA HEIH in AML patients was significantly higher than that in patients with non-hematological malignancies (P <0.01). Moreover, AML patients with high white blood cell count (WBC), CEBPA and FLT3 mutations, poor efficacy, and poor prognosis often showed higher expression of lncRNA HEIH, and patients with high lncRNA HEIH expression showed a shorter overall survival (OS).lncRNA HEIH shows an unique molecular biological significance in AML patients, which may provide a new approach for diagnosis, monitoring and targeted therapy of AML.